ArticleJournal of cellular and molecular medicine2026
Oxypaeoniflorin Ameliorates Titanium Particle-Stimulated Osteolysis by Targeting Nrf2 to Reprogram Mitochondrial Homeostasis in Osteoclasts.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Wear debris surrounding implants plays a crucial role in the development of periprosthetic osteolysis (PPO) by inducing the aggregation of osteoclasts around the prosthesis. Oxypaeoniflorin (OPF), a derivative of Paeoniflorin, is primarily sourced from the root of the traditional Chinese medicine peony and possesses anti-inflammatory and antioxidant properties. Currently, the effects of OPF on osteoclast activation and particle-induced bone resorption remain unclear. In this study, we examined the regulatory effect of OPF on titanium particle-induced bone erosion in vivo and utilized bone marrow macrophages to investigate the impact of OPF on osteoclast differentiation and resorptive function along with its potential mechanisms. Our results indicate that in vitro, OPF inhibits RANKL-induced osteoclastogenesis, osteoclast-dependent resorption, and the expression of osteoclast marker genes through the activation of Nrf2-mediated oxidative stress signalling. Furthermore, in vivo, OPF suppressed titanium particle-induced bone loss and osteoclast formation. Our data further confirm the protective effect of OPF against titanium particle-induced osteolysis from a novel perspective of preventing bone erosion, establishing OPF as a suitable drug for the prevention of PPO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.